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Abstract
There is unequivocal evidence that alpha-synuclein plays a pivotal pathophysiological role
in neurodegenerative diseases, and in particular in synucleinopathies. These disorders
present with a variable extent of cognitive impairment and alpha-synuclein is being explored
as a biomarker in CSF, blood serum and plasma. Considering key events of aging that in-
clude proteostasis, alpha-synuclein may not only be useful as a marker for differential diag-
nosis but also for aging per se. To explore this hypothesis, we developed a highly specific
ELISA to measure alpha-synuclein. In healthy males plasma alpha-synuclein levels corre-
lated strongly with age, revealing much lower concentrations in older (avg. 58.1 years) com-
pared to younger (avg. 27.6 years) individuals. This difference between the age groups was
enhanced after acidification of the plasmas (p<0.0001), possibly reflecting a decrease of
alpha-synuclein-antibody complexes or chaperone activity in older individuals. Our results
support the concept that alpha-synuclein homeostasis may be impaired early on, possibly
due to disturbance of the proteostasis network, a key component of healthy aging. Thus,
alpha-synuclein may be a novel biomarker of aging, a factor that should be considered
when analyzing its presence in biological specimens.
Introduction
Alpha-synuclein, an aggregation-prone and amyloid-forming protein, plays a pivotal role in the
pathogenesis of synucleinopathies such as Parkinson’s disease (PD), dementia with Lewy bodies
(DLB) and multiple system atrophy (MSA) and is being explored as a biomarker in cerebrospi-
nal fluid (CSF), blood plasma, and serum [1,2]. Recently, the aggregation of disease-related
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proteins in physiological aging has been attributed to altered protein homeostasis (proteostasis)
[3,4]. This was suggested to represent a biomarker of aging that could modulate life span and
cause neurodegeneration [5,6]. Identification and application of such biomarkers may advance
longevity and help influence or prevent concomitant illnesses. Other markers of aging or frailty
are related to the immune system, such as innate or adaptive immune cells (immunosenescence)
[7,8], cytokines [9], inflammation and autoimmunity [10], and genetic or epigenetic signatures
[11], such as telomere length or DNAmethylation state, respectively.
Alpha-synuclein is one of two other amyloidogenic key proteins, specifically, amyloid beta
(Abeta) and tau, which play a major pathophysiological role in the three most common
neurodegenerative diseases leading to dementia, namely Alzheimer’s disease (AD), DLB and
Parkinson’s disease dementia (PDD). The three proteins also appear to act in concert by co-
aggregation [12–16] and propagation through the nervous system tissue in a prion-like manner
leading to neuronal death [14,17,18].
Reliable, high throughput and cost-effective measurement of alpha-synuclein in biological
fluids is of crucial importance for clinical research. However, published concentrations in bio-
logical samples with high matrix effects such as plasma or serum vary widely. We developed a
highly specific and validated ELISA for the measurement of total alpha-synuclein and analyzed
plasma from healthy males (n = 80) in a younger (range 22–35 years) and older age group (50–
69 years). Plasma from the same specimens, acidified to dissociate alpha-synuclein-protein
complexes, was analyzed in parallel. Our findings may impinge on studies of the pathophysio-
logical mechanisms of aging involving impaired proteostasis and have implications for the pre-
clinical diagnosis of neurodegenerative diseases.
Materials and Methods
Plasma samples
The ethics committee of the Eberhard-Karls-University Tübingen approved this study (ethics
nr. 314/06). Eighty blood plasmas from healthy male blood donors and 13 cell free CSF samples
from individuals recruited by the Department of Transfusion Medicine and Department of
Psychiatry and Psychotherapy, Eberhard-Karls-University Tübingen were analyzed. Written
informed consent was received by all individuals participating in the study. If capacity to con-
sent of participants was compromised by any means, based on neuropsychological testing and
physicians’ judgment, legal guardians consented on their behalf. All participants who declined
to participate or otherwise did not participate in the study were not disadvantaged in any
other way. Individuals did not suffer from a physical or brain disorder and were unremarkable
in cognition.
Blood and/or CSF were taken between 9 and 12 a.m., processed within 2 hours (h) after col-
lection, aliquoted and immediately frozen at -20°C. In detail, blood was drawn into polypropyl-
ene (pp) lithium-heparin tubes (Sarstedt-S-Monovette, Germany). CSF was collected from the
lumbar cistern (between lumbar vertebrae L2-L5) though a 22 G spinal needle (Becton, Dickin-
son and Company, USA) into a 13 ml pp tube (Sarstedt). After centrifugation at 2000xg for 15
minutes at 4°C, cell-free plasma and CSF were aliquoted into polypropylene Eppendorf micro-
centrifuge tubes (Eppendorf, Hamburg, Germany) or Nunc Cryo tubes (Thermo Fisher Scien-
tific, MA, USA).
Data and statistical analysis
Statistical evaluation and regression analysis were carried out as indicated using the GraphPad
Prism 5 software (La Jolla, CA, USA). Groups were compared by unpaired or paired two-tailed
t-test, as indicated. Demographics were analyzed by unpaired two-tailed t-test. Correlations
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were assessed by Spearman correlation. The significance level was set at p<0.05 (p<0.001,
highly significant; p = 0.001–0.01, very significant; p = 0.01–0.05, significant;>0.05 not
significant).
Measurement of alpha-synuclein concentration
Human alpha-synuclein was measured by a highly specific and sensitive sandwich enzyme-
linked immunosorbent assay (ELISA) developed in our laboratory and described below.
Human recombinant alpha-synuclein produced in E. coli was analyzed for purity by western
immunoblot and used as a positive control and to generate a standard curve. Ninety six well
plates (Nunc Maxisorb, Thermo Fisher Scientific, MA, USA) were coated with 3 μg/ml mono-
clonal mouse anti-alpha-synuclein IgG1 kappa, clone syn211 (Sigma-Aldrich, Deisenhofen,
Germany) in carbonate-bicarbonate buffer at pH 9,6 and incubated overnight at 4°C. Plates
were washed in PBS/Tween (PBS, Sigma-Aldrich, 0.1% Tween-20) and blocked in TBS/Tween
containing 2% bovine non-fat dried milk protein (Sigma-Aldrich). Duplicate wells were incu-
bated with plasma diluted 1:5 or with undiluted CSF. The human samples from the two age
groups were pipetted on the plate in a randomized order. Serial dilutions of standards were pre-
pared by using human recombinant alpha-synuclein in PBS/Tween. Beta-synuclein in PBS/
Tween served as a negative control. After washing wells were incubated with polyclonal rabbit
anti-alpha/beta/gamma-synuclein IgG (FL-140) sc-10717 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) diluted 1:5000 in PBS/Tween for 1 h, followed by incubation with biotinylated
goat F(ab’)2 anti-rabbit IgG (H+L chain specific) (Southern Biotech, AL, USA) diluted 1:5000
in PBS/Tween for 1 h. Streptavidin-POD enzyme conjugate (Roche, Mannheim, Germany)
was used as an amplification step and tetramethylbenzidine (TMB) (Sigma-Aldrich) as the
peroxidase substrate. The colour reaction was stopped after 30 minutes. Absorbance (OD, opti-
cal density) as a measure of specific human alpha-synuclein was measured at 450 nm in an
ELISA reader (Sunrise, Tecan, Switzerland). All measured sample concentrations were cor-
rected against the background control (sample blank, only plasma omitted) to calculate alpha-
synuclein concentrations produced by the specific signal.
Blocking of plasma alpha-synuclein
The specificity of measured plasma alpha-synuclein was demonstrated in a blocking assay by
preincubation of plasma with monoclonal syn211 anti-alpha-synuclein antibody at 160 ng/ml
for 2 h and 20°C prior to ELISA analysis. In addition, a solid phase alpha-synuclein preabsorp-
tion assay by means of a well to well plasma transfer was performed.
Spike-and-recovery
To determine whether analyte detection is altered by sample matrix, i.e. plasma component, a
known amount of alpha-synuclein was spiked into a plasma sample. If recovery is decreased,
components of the sample matrix likely cause the difference. Spike-recovery assays were per-
formed on plasmas from 11 individuals at the utilized dilution at 1:5.
Acidification of plasma
Plasma was acidified to dissociate undetectable alpha-synuclein complexes with antibodies or
chaperone-like proteins. Acidification was carried by methods adapted fromMorgan et al. [19]
after rigorous testing. In detail, 10 μl of plasma was diluted with 30 μl PBS/Tween buffer and
acidified with 5 μl 1M glycine-acetate in PBS buffer, pH = 2.0, or control buffer, pH = 7.0, incu-
bated at 20°C for 20 minutes in Eppendorf tubes on a shaker and subsequently neutralized
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with 5 μl Tris-HCl buffer, pH = 9.0. Final volume was 50 μl (plasma dilution of 1:5) and a neu-
tral pH-value was ascertained using pH indicator strips (Sigma-Aldrich).
SDS-PAGE and western blotting
Electrophoresis was performed with a 15% SDS polyacrylamide slab minigel and a Tris-glycine
buffer system (SDS-PAGE). Human recombinant alpha-synuclein (600 ng) was loaded and
subjected to 20 mA current until the bromophenol blue dye (Sigma-Aldrich) approached the
end of the gel. Proteins were transferred at 150 mA for 4 h onto a 0.1 μm pore-size nitrocellu-
lose membrane using a TRIS-glycine-methanol buffer. The membrane was washed in 0.1%
Tween-20/PBS and blocked for 1 h with 5% skimmed milk (SM) (Sucofin, TSI GmbH & Co.
KG, Zeven, Germany)/PBS. After washing, the membrane was cut into strips and incubated
overnight at 4°C with 2% SM/PBS with 1:500 rabbit anti-alpha/beta/gamma-synuclein IgG
(FL-140) or 1:1000 mouse syn211 anti-alpha-synuclein IgG antibody. After washing and block-
ing, strips were incubated with anti-rabbit or anti-mouse IgG-alkaline phosphatase (AP) at
1:5000 for 2 h in 2% SM/PBS. The immunoblot was visualized using BCIP (5-bromo-4-chloro-
3-indolyl-phosphate) with NBT (nitro blue tetrazolium) (Promega, Mannheim, Germany) for
detection of AP activity.
Results
Population and Demographics
Details of the population demographics are shown in Table 1. Age difference between the 80
healthy males was highly significant by unpaired two-tailed t-test, p<0.0001. Demographics of
CSF samples were not analyzed because alpha-synuclein concentrations mostly fell below the
detection limit of the assay (described below).
Measurement of human alpha-synuclein
The ELISA was extensively tested with various modifications to achieve maximum specificity
and reliability. After testing a wide range of plasma concentrations a dilution of 1:5 was chosen,
because it provided alpha-synuclein concentrations generally within the linear range (0.3–10
ng/ml), well above the lower detection limit of the assay (300 pg/ml), which was 2-fold the un-
specific background level given by a blank of 0.1 OD. Plasma samples below the detection limit
were arbitrarily set to 100 pg/ml. The standard curve is illustrated in Fig 1. Measurements were
replicated in 3 independent assays, the inter-assay coefficient of variation (%CV) measuring
control plasma was 14%. In order to attain the highest consistency for a reliable comparison of
alpha-synuclein concentrations, only data are shown that were generated within the same, last
experimental run containing all samples.
Table 1. Alpha-synuclein concentration in native and acidified plasma in a younger and older group of healthy males.
n age (y) alpha-synuclein native (ng/ml) alpha-synuclein acidiﬁed (ng/ml)
young 40 27.6 (26) +/- 0.7 CI 26.2–28.9 11.4 (4.3) +/- 3.2 CI 5.0–17.9 21.8 (9.7) +/- 4.8 CI 12.0–31.6
old 40 58.1 (58)+/- 0.7 CI 56.6–59.6 3.6 (1.5) +/- 1.4 CI 0.8–6.4 6.9 (3.6) +/- 2.6 CI 1.6–12.2
Data are shown as mean (median) +/- SE. SE = standard error, CI = 95% conﬁdence interval of the mean, n = number of individuals, y = years.
doi:10.1371/journal.pone.0123444.t001
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Stability of alpha-synuclein in standards and plasma
We observed a diminution of the alpha-synuclein concentrations in standard solutions upon
storage at room temperature. To investigate this observation in greater detail a 6 ng/ml alpha-
synuclein standard solution was preincubated for various time periods before performing the
assay. In parallel, western immunoblotting from same standards visualized novel conforma-
tions or aggregates. Compared to freshly thawed and diluted monomeric alpha-synuclein pre-
incubation of equimolar concentrations of recombinant alpha-synuclein in PBS for 3, 18 and
32 h at 37°C resulted in a decrease of alpha-synuclein concentration by 21, 66 and 78%, respec-
tively, as measured by ELISA (Fig 2) and visualized by western immunoblot (Fig 3). This was
reflected by appearance of a higher molecular weight band at 70 kDa and time-dependent fad-
ing of the monomeric alpha-synuclein band at 14 kDa when probing with a polyclonal anti-
alpha/beta/gamma-synuclein antibody (FL-140), lane 1–4 (Fig 3). A higher molecular weight
band was not detected with monoclonal anti-alpha-synuclein antibody (syn211), lane 5–9 (Fig
3). No bands or degradation products could be observed below the alpha-synuclein band. In
contrast to standard solution, alpha-synuclein concentrations in native plasma were more sta-
ble. Leaving undiluted plasmas at 20°C for 3, 24 or 48 h, resulted in an average decrease of 5, 13
and 17%, respectively. Preincubation of plasma at 37°C for 3 and 24 h lead to mean reduction
of 5 and 16%, respectively. Furthermore, three freeze-thaw cycles of undiluted plasmas did not
alter the alpha-synuclein concentrations significantly (data not shown).
Specificity of alpha-synuclein measurements
To validate the specificity of plasma alpha-synuclein measurements, native plasma was prein-
cubated with monoclonal syn211 anti-alpha-synuclein antibody to block the alpha-synuclein
binding site. Syn211-blocked and untreated native plasma samples were incubated in parallel
and subsequently measured by ELISA. Resulting alpha-synuclein concentrations were reduced
by a mean of 71%, confirming the specificity of the measurements. Similarly, solid phase preab-
sorption of alpha-synuclein by a well-to-well transfer resulted in loss of the protein. Dilution of
plasma yielded proportional decreases of alpha-synuclein concentrations (linearity-of-
Fig 1. ELISA standard curve for alpha-synuclein.Detection limit of the assay was set at 300 pg/ml
(described in results). SD bars are from duplicate measurements.
doi:10.1371/journal.pone.0123444.g001
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Fig 2. Concentration of an alpha-synuclein standard solution decreases with preincubation.
Incubation of freshly diluted alpha-synuclein at 6 ng/ml in PBS for 3, 18 and 32 h at 37°C decreased ELISA-
measured alpha-synuclein levels by 21, 66 and 78%, respectively.
doi:10.1371/journal.pone.0123444.g002
Fig 3. Western immunoblot of alpha-synuclein standard solution after preincubation. Lane 1–4 was
probed with anti-alpha/beta/gamma-synuclein antibody (FL-140), lane 5–9 with anti-alpha/beta/gamma-
synuclein antibody (syn211). Compared to freshly diluted alpha-synuclein in PBS at 6 ng/ml (0 h, lane 1 and
lane 5), incubation at 37°C for 3, 18, 32 h (lane 2, 3, 4, respectively) resulted in fading of the monomeric
alpha-synuclein band at 14 kDa and appearance of a higher molecular weight band using FL-140, whereas
no higher molecular weight band was detected with syn211 after 1, 3, 5, 10 h (lane 6, 7, 8, 9, respectively).
doi:10.1371/journal.pone.0123444.g003
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dilution). In spike-and-recovery assays three native plasma samples N1, N2 and N3 containing
0.23,<0.03 (below limit of assay) and 0.29 ng/ml alpha-synuclein, respectively, were spiked
with 0.625 and 1.25 ng/ml synuclein, equivalent to the amount that was added to standard so-
lutions (s) (Fig 4). Recovery (%) of spiked alpha-synuclein was calculated by subtraction of the
internal plasma alpha-synuclein. Eight additional plasmas were spiked with 5 ng/ml alpha-
synuclein, recovery is illustrated (Fig 5). Notably, recovery appeared to decline with increasing
amounts of alpha-synuclein spiked into the plasma. When native unspiked plasmas N1 and N3
were blocked with syn-211, alpha-synuclein measurements diminished to 0.03 ng/ml and
below the detection limit of the assay (<0.03 ng/ml), respectively. Finally, no specific signal or
crossreactivity was observed when using recombinant β-synuclein (not shown).
Plasma alpha-synuclein
Alpha-synuclein concentrations were measured in native plasma of 80 healthy control males,
divided into a younger and older age group (Table 1). Plasma was acidified to dissociate alpha-
synuclein-antibody or protein complexes and thus liberate masked alpha-synuclein for detec-
tion. Mean and median alpha-synuclein concentrations in native and acidified plasma are
given in Table 1.
Acidification resulted in higher alpha-synuclein concentrations in most plasmas. In detail,
30 out of 40 individuals (75%) in the younger group and 28 of 40 (70%) in the older group
showed an increase. This was highly significant for both groups according to one-tailed Wil-
coxon matched pairs test, p<0.0001. The increase of plasma alpha-synuclein levels was much
Fig 4. Spike and recovery. Three native plasmas N1, N2 and N3 were spiked (sp) with alpha-synuclein
(alpha-syn) at 0.625 ng/ml and 1.25 ng/ml, equivalent to the amount that was added to standard solutions (S).
Recovery (%) of spiked alpha-synuclein was calculated by subtraction of the internal alpha-synuclein in the
native plasma (given in results).
doi:10.1371/journal.pone.0123444.g004
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stronger in the younger than older individuals. When calculating dissociation factors by
dividing the acidified and native alpha-synuclein concentration from each individual lower
multipliers were observed in older compared to younger individuals, very significant by Mann
Whitney test, p = 0.0093 (Fig 6)
There were much higher alpha-synuclein concentrations in native plasma from younger
compared to older individuals, highly significant by MannWhitney test, p = 0.0005, shown in
Fig 7. Remarkably, for acidified plasma the difference between the age groups was even more ev-
ident, p<0.0001. Eleven of 80 (14%) native and 3 of 80 (4%) acidified plasma samples were
below the detection limit (300 pg/ml) of the assay. Ten of the total 14 (71%) negative plasma
samples were from older individuals. In contrast, the alpha-synuclein concentration in CSF was
approximately 10-folds lower than in plasma. Nine of 13 CSF samples (69%) were below the de-
tection limit of the assay (300 ng/ml), and thus the results were unsuitable for further analysis.
In Fig 8 the alpha-synuclein concentrations of native and acidified plasma are plotted against
age for each individual, the respective linear regression line are indicated. Elevations between
lines were significantly different, p = 0.039, and slopes differed significantly from zero with
p = 0.046 and p = 0.021 for native and acidified plasma, respectively. The Spearman correlation
was very significant for native samples, p = 0.0093, r = -0.3 and after acidification, p = 0.0019,
r = -0.34. No correlation of alpha-synuclein concentrations with age was observed within the
younger or older group, signifying falling alpha-synuclein plasma levels after the age of 35.
Discussion
Prevention of age-related diseases is of pivotal interest to ascertain quality of life. To reach this
goal, identification of aging biomarkers that reflect biological rather than chronological age, de-
lineate tempo of aging and indicate impending life-span would be vital [10]. In addition, such
biomarkers could potentially reveal dormant age-related diseases like movement and cognitive
disorders and facilitate their primary prevention, reducing incidence and prevalence of disease.
Thereby, compliance and sustained life-style changes could be achieved.
Fig 5. Spike and recovery. Eight native plasmas were spiked with 5 ng/ml alpha-synuclein, recoveries are
illustrated in a box plot*, mean recovery was 70.4%.* The boxes upper and lower borders represent the 25th
and 75th percentile, whiskers indicate the 10 to 90 percentile, lines within the box mark the median (thin line)
and the mean (bold line).
doi:10.1371/journal.pone.0123444.g005
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Aging is characterized by biological key events which involve protein homeostasis (proteos-
tasis), DNA damage, telomere shortening, epigenetic alterations, mitochondrial dysfunction,
caused by reactive oxygen species (ROS) or mitochondrial (mt)DNA mutations [20,21]. Based
on evidence that protein aggregation constitutes an inherent phenomenon of aging [3,4] we ex-
plored alpha-synuclein plasma levels which may be altered in a dysfunctional proteostasis net-
work, thought to influence life span already in early adulthood [5,6]. Homeostasis of alpha-
synuclein may be disturbed early on by proteasomal and lysosomal malfunction that impair
clearance of damaged or denatured proteins [22,23] or by lack of molecular chaperones or nat-
ural antibodies that protect or refold proteins [24–27]. Mutant and/or structurally altered
alpha-synuclein may result in gain of toxic or loss of function by causing cell injury and death
(i.e. oligomers or protofibrils) or by being probably inert (i.e. fibrils in Lewy bodies). Thus,
maintaining protein function and appropriate tissue concentrations may improve healthy
aging [28,29].
Alpha-synuclein was discovered in 1988 in CNS neurons [30] and cloned from AD brain
tissue in 1993 [31]. In 1997 it was detected in hematopoietic cells [32], and as of 2000 in CSF
and serum [33,34]. Subsequently, alpha-synuclein was explored as a biochemical marker in
neurodegenerative diseases, particularly in PD as the prototypic synucleinopathy [35], re-
viewed in [36–39]. Alpha-synuclein is a principal component of Lewy bodies [40,41] the patho-
logical hallmark of synucleinopathies [42]. In AD, a prototype tauopathy, up to 60% of patients
have Lewy body pathology in the CNS [43,44]. In contrast to Abeta plaques, Lewy bodies and
aggregates of alpha-synuclein are well correlated with cognitive impairment not only in PD but
also in AD [45,46], signifying alpha-synuclein as a prime candidate biomarker. Hence, accurate
Fig 6. Dissociation factor after plasma acidification young vs. old. Box plots* of dissociation factors,
calculated by dividing the acidified and native plasma alpha-synuclein concentration of each individual
sample. Lower dissociation factors were observed in older individuals, very significant by MannWhitney test,
p = 0.0093.
doi:10.1371/journal.pone.0123444.g006
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quantification of alpha-synuclein in biological fluids is crucial, albeit complicated due to low
concentrations and its tendency to self-aggregate and adhere to plastic surfaces [47]. We ob-
served diminishing alpha-synuclein levels after in vitro aggregation of standard solutions,
which has also been observed in ELISAs measuring Abeta [48]. In comparison, leaving undilut-
ed plasma for prolonged time at room temperature led to a modest reduction in the alpha-
synuclein concentrations. Accordingly, standard operating procedures for sample handling
and assay conditions should be defined; a unified effort to standardize measurements to im-
prove reproducibility is ongoing [49].
Many studies have addressed the analysis of alpha-synuclein in CSF [36,37] and to a lesser
extent in blood plasma or serum [50–62]. Available data is conflicting and plasma or serum
concentrations vary, mostly between 4–48 ng/ml. No consistent differences between patients
and controls or within healthy populations could be established. We detected low alpha-
synuclein plasma levels of 3.6 ng/ml (mean) in healthy older males (mean 58 years). Alpha-
synuclein negatively correlated with age showing significantly higher concentrations of 11.4
ng/ml (mean) in younger individuals (mean 28 years). Plasma acidification served to enhance
this difference which may reflect a decrease in alpha-synuclein-antibody complexes or chaper-
one activity in the elderly. To our knowledge similar observations have not been reported pre-
viously and could be related to the inclusion of younger individuals in addition to
Fig 7. Box plots* of alpha-synuclein levels in native and acidified plasma. (a) Younger in comparison to
older individuals revealed higher alpha-synuclein levels, highly significant by MannWhitney test for native,
p = 0,0005 and acidified plasmas, p<0.0001. (b) Plasma acidification increased alpha-synuclein
concentrations in both age groups, highly significant by a one-tailed Wilcoxon matched pairs test, p<0.0001.
The additional horizontal short line in the box represents the mean.
doi:10.1371/journal.pone.0123444.g007
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methodological differences. Our assay was rigorously validated and background levels were
very low. Interestingly, Brighina et al. observed a positive correlation of alpha-synuclein levels
with age in lymphomonocytes from healthy controls [63], in accordance with the notion that
intracellular accumulation of alpha-synuclein could lead to lower plasma levels.
The above concept that alpha-synuclein may be complexed with plasma components such
as antibodies or other binding proteins which are liberated by acidification is supported by loss
of recovery after spiking alpha-synuclein into the plasma sample. Because higher molecular
weight aggregates of alpha-synuclein were not detected in the western immunoblot when prob-
ing with coating antibody (syn211), it is reasonable to assume that the detecting epitope can be
conformationally masked in aggregates, which then remain undetected in the assay. This may
partly explain the decrease of alpha-synuclein levels after prolonged incubation of plasma or
standard solution.
Body homeostasis is characterized by a subtle equilibrium of de- and regeneration, renewal
and removal of damaged cells and proteins. Protein turnover is critically reduced in later life
[64] resulting in catabolism and accumulation of damaged proteins in muscle and brain [65].
Already at the end of the second life decade this balance may become instable and skewed to-
wards senescence and degeneration. As such, elite level performance in sports will top out at
24–28 years of age, an age range represented by our younger healthy males, and declines there-
after [66,67]
Alpha-synuclein may have broad implications for healthy aging because it presumably plays
a key role in synaptic plasticity [68,69]. It is critical for memory formation and lifelong learning
that declines in healthy humans within age-adjusted norms, also known as age-related memory
impairment, but is only disrupted in neurodegenerative disease. Also, alpha-synuclein may trig-
ger transient or bland symptoms of unknown significance that may occur in healthy people or
precede disease by many years or possibly even decades. Interestingly, animals do not spontane-
ously develop PD and complete loss of alpha-synuclein in knock-out mice does not cause overt
Fig 8. Linear regression of age with alpha-synuclein concentration in native and acidified plasma.
Alpha-synuclein decreased with age and was enhanced by acidification. Spearman correlation was very
significant for native samples, p = 0.0093, r = -0.3, after acidification, p = 0.0019, r = -0.34.
doi:10.1371/journal.pone.0123444.g008
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disease, except for deficits in the dopamine system of the basal ganglia [70]. These mice show
normal development and, surprisingly, resistance to mitochondrial toxins such as MTPT [71].
The potential relevance of alpha-synuclein as an aging biomarker is further supported by its
characteristic to signify a broad spectrum of neurodegenerative diseases, presenting with vari-
able neurological, psychiatric or somatic symptoms caused by more or less widespread alpha-
synuclein accumulation or deposition in the CNS and PNS. Clinical symptoms may include ex-
trapyramidal signs (EPS), cognitive impairment, dementia, affective disorders, psychosis and
autonomic symptoms, i.e. sleep disturbances and incontinence. In addition, it is conceivable
that function of other tissues and cell types such as leukocytes that express alpha-synuclein
may be altered [32,56,72]. Indeed, recent work revealed that macrophages/microglia expressing
alpha-synuclein at higher levels exhibit impaired cytokine production and immune function
[73]. Similar to Abeta, alpha-synuclein forms toxic soluble intermediates, such as oligomers or
protofibrils [74] when reaching critical concentrations that likely play pathophysiological key
roles in a diverse spectrum of neurodegenerative diseases. In this context, it is of note that
alpha-synuclein gene multiplications or missense mutations raise alpha-synuclein levels in
blood and brain and lead to early onset and severe forms of PD or DLB, demonstrating that
gene dosage alone causes variable disease phenotypes [75–79].
In summary, our data reveal that alpha-synuclein levels in blood plasma from healthy indi-
viduals markedly decrease between the 3rd and 5th decade of life. This disturbed proteostasis
may relate to the frailty process but not a particular disease, possibly caused by dysregulation
of cellular lysosomes and proteasomes, antibodies or molecular chaperones that modify alpha-
synuclein levels and conformation, respectively. Thus, alpha-synuclein may reflect biological
age and qualify as a candidate biomarker of aging to advance life expectancy. Moreover, our
findings support the idea that imbalances of alpha-synuclein levels may influence neuronal vul-
nerability that increases with age, a main risk factor for neurodegenerative disease [80].
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